연구
연구업적
최근 5년 연구업적 현황
| 연도 | 2025년 | 2024년 | 2023년 | 2022년 | 2021년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 196편 | 179편 | 173편 | 163편 | 184편 |
| 공동 | 132편 | 147편 | 120편 | 115편 | 136편 | |
| 합계 | 328편 | 326편 | 293편 | 278편 | 320편 | |
3315. Dual T-cell depletion with individually tailored anti-thymocyte globulin and attenuated dose of post-transplant cyclophosphamide in haploidentical peripheral stem cell transplantation
Dong Hyun Kim, Dong-Yeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Ja Min Byun, Junshik Hong
Sci Rep . 2024 Jun 16;14(1):13885
Link
3314. Unraveling the impact of lysosomal dysfunction on myeloproliferative neoplasm
Hyundong Yoon, Dohoon Lee, Seulki Song, Bonil Koo, Jihyun Park, Tae Kon Kim, Sun Kim, Sheehyun Kim, Junshik Hong, Ja Min Byun, Dong‐Yeop Shin, Inho Kim, Youngil Koh, Sung‐Soo Yoon
Cancer Med . 2024 Sep;13(18):e70238
Link
3313. Efficacy and Safety of Bispecific T-Cell Engagers in Relapsed/Refractory Multiple Myeloma: A Real-World Data-Based Case-Controlled Study
Suein Choi, Ja Min Byun, Sung-Soo Park, Jinsun Han, Sieun Oh, Seungpil Jung, Hyejoon Park, Seunghoon Han, Jung Yeon Lee, Youngil Koh, Young-Woo Jeon, Seung-Ah Yahng, Seung-Hwan Shin, Sung-Soo Yoon, Chang-Ki Min
Transplant Cell Ther . 2024 Nov 26:S2666-6367(24)00779-6
Link
3312. Phase II trial of imatinib mesylate in patients with PDGFRA/B‐negative hypereosinophilic syndrome
Dong Hyun Kim, Seokhyeon Kim, Seonyang Park, Ja Min Byun, Junshik Hong, Dong‐Yeop Shin, Inho Kim, Soo Mee Bang, Jeong‐Ok Lee, Ji Yun Lee, Sang‐A Kim, Ki Hwan Kim, Yeun‐Jun Chung, Seung‐Hyun Jung, Youngil Koh, Sung‐Soo Yoon
Br J Haematol . 2024 Dec;205(6):2305-2314
Link
3311. Immunomodulatory effects of trastuzumab deruxtecan through the cGAS-STING pathway in gastric cancer cells
Kyoung-Seok Oh 1, Ah-Rong Nam 1, Ju-Hee Bang 1, Yoojin Jeong 1, Sea Young Choo 1, Hyo Jung Kim 1, Su In Lee 1, Jae-Min Kim 1 2, Jeesun Yoon 3, Tae-Yong Kim 1 3, Do-Youn Oh 4 5 6
Cell Commun Signal. 2024 Oct 24;22(1):518.
Link
3310. HER2-targeted therapies beyond breast cancer - an update
Jeesun Yoon 1, Do-Youn Oh 2 3 4
Nat Rev Clin Oncol. 2024 Sep;21(9):675-700
Link
3309. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Do-Youn Oh 1, Aiwu Ruth He 2, Mohamed Bouattour 3, Takuji Okusaka 4, Shukui Qin 5, Li-Tzong Chen 6, Masayuki Kitano 7, Choong-Kun Lee 8, Jin Won Kim 9, Ming-Huang Chen 10, Thatthan Suksombooncharoen 11, Masafumi Ikeda 12, Myung Ah Lee 13, Jen-Shi Chen 14, Piotr Potemski 15, Howard A Burris 3rd 16, Vikas Ostwal 17, Suebpong Tanasanvimon 18, Chigusa Morizane 4, Renata E Zaucha 19, Mairéad G McNamara 20, Antonio Avallone 21, Juan E Cundom 22, Valeriy Breder 23, Benjamin Tan 24, Satoshi Shimizu 25,
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704.
Link
3308. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Miao-Zhen Qiu 1, Do-Youn Oh 2, Ken Kato 3, Tobias Arkenau 4, Josep Tabernero 5, Marcia Cruz Correa 6, Anastasia V Zimina 7, Yuxian Bai 8, Jianhua Shi 9, Keun-Wook Lee 10, Jufeng Wang 11, Elena Poddubskaya 12, Hongming Pan 13, Sun Young Rha 14, Ruixing Zhang 15, Hidekazu Hirano 16, David Spigel 17, Kensei Yamaguchi 18, Yee Chao 19, Lucjan Wyrwicz 20, Umut Disel 21, Roberto Pazo Cid 22, Lorenzo Fornaro 23, Ludovic Evesque 24, Hongwei Wang 25, Yaling Xu 26, Jiang Li 25, Tao Sheng 25, Silu Yang 27,
BMJ. 2024 May 28:385:e078876.
Link
3307. Complete genome sequence of an enterotoxigenic Bacteroides fragilis strain 2-078382-3 from an infant with diarrhea
Lee E, Kang H, Song HB, Yeom J.
Microbiol Resour Announc. 2024 Dec 20:e0058724
Link
3306. Experimental evolution under different nutritional conditions changes the genomic architecture and virulence of Acinetobacter baumannii
Yun S, Min J, Han S, Sim HS, Kim SK, Lee JB, Yoon JW, Yeom J, Park W.
Commun Biol. 2024 Oct 5;7(1):1274
Link